About this trial
The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are:
What are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler "native T1" measurement (without contrast dye) instead of the more complex "ECV" measurement (which requires contrast dye) for diagnosis?
Patients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.
Cardiomyopathies (HCM, DCM, RCM, ACM)
Infiltrative disorders (cardiac amyloidosis, Fabry disease)
Inflammatory conditions (acute/chronic myocarditis)
Disqualifiers
Presence of multiple cardiomyopathy diseases or risk factors simultaneously
Contraindications to CMR examination
Poor image quality precluding accurate T1 mapping analysis
Incomplete clinical data for definitive diagnosis confirmation
Trial population
The study population comprises a diverse cohort of patients with a comprehensive spectrum of myocardial conditions, including Fabry disease, iron overload, atrial fibrillation, hypertension, aortic stenosis, chronic and acute myocardial infarction, hypertrophic, dilated, restrictive, and arrhythmogenic cardiomyopathies, acute and chronic myocarditis, cardiac amyloidosis, cardiac tumors, congenital heart disease, and cases of suspected transplant rejection. This population represents a wide array of pathophysiological processes affecting the myocardium, ensuring broad clinical relevance and generalizability of the study findings.
Trial design
Cohort
Prospective
Treatments tested in this trial
Magnetic Resonance Imaging with Contrast
Diagnostic testParticipants in this arm undergo a single, standardized cardiac MRI scan with gadolinium-based contrast agent.
Treatment groups
Trial outcomes
Primary outcomes
Ranges of T1 mapping values
Sponsors and contacts
Click on the lead sponsor to view all of their trials.